sitagliptin + saxagliptin + alogliptin

This medication is a **combination of three dipeptidyl peptidase-4 (DPP-4) inhibitors**: sitagliptin, saxagliptin, and alogliptin. Each of these small molecule agents is used orally to treat type 2 diabetes mellitus. They inhibit the DPP-4 enzyme, which prolongs the activity of incretin hormones—primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This action increases insulin secretion and suppresses glucagon secretion in a glucose-dependent manner, leading to improved blood glucose control. Individually, these drugs are indicated for type 2 diabetes, and have been developed and marketed by separate companies. No evidence was found for the existence or approval of a triple combination product containing all three agents. Combining multiple DPP-4 inhibitors is not a recommended or supported therapeutic strategy; their mechanisms overlap, and guidelines advise against their concurrent use due to a lack of additive benefit and potential for unnecessary adverse effects[5]. Each agent is approved as monotherapy or in combination with other drugs (often metformin) for type 2 diabetes, but not together.